EQRx Inc

EQRx — Investor Presentation (January 2022)

36 slides from EQRx's investor presentation, Jan 10, 2022

  1. Slide 1: New Pharma

    NEW PHARMA

  2. Slide 2: Disclaimer

    DISCLAIMER ‘This presentation ths “Presentation” relates to EGR ne. (together with ts subsclaris, “EOR"), EQRx is 9 now typeof pharmaceutical company’ committed to developing and delivering innovative medicines to patient ot radealy lover prices Launehed in Janisry 2020, EGRx is purpose-bult st scal

  3. Slide 3: Our Mission

    OUR MISSION IMPROVE HEALTH FOR ALL WITH GREAT, INNOVATIVE, AFFORDABLE MEDICINES

  4. Slide 4: What is EQRx?

    What is EAR?

  5. Slide 5: EQRx is building a platform at scale

    EQRx IS BUILDING A PLATFORM AT SCALE INNOVATIVE POPULATION THERAPIES ACCESS

  6. Slide 6: Payers & health system partners will drive adoption

    PAYERS & HEALTH SYSTEM PARTNERS WILL DRIVE ADOPTION INNOVATIVE POPULATION THERAPIES ACCESS

  7. Slide 7: Growing catalog of high-quality, innovative medicines at radically lower prices

    GROWING CATALOG OF HIGH-QUALITY, INNOVATIVE EUAN Sed es] AT RADICALLY LOWER PRICES POPULATION ACCESS INNOVATIVE THERAPIES

  8. Slide 8: How can we do this?

    HOV CAN WE DO THIS?

  9. Slide 9: By fundamentally reengineering the model

    By fundamentally reengineering the model and creating

  10. Slide 10: Our platform is designed to align incentives across the ecosystem

    OUR PLATFORM IS DESIGNED TO ALIGN INCENTIVES ACROSS THE ECOSYSTEM wore, NeLNE MORE ACCESS = MORE SAVINGS & cataioc vem LA POPULATION a THROUGH @@qiaies RADICALLY LOWER wore SYSTEM PRICES SAVINGS & EXPANDED ‘ACCESS INNOVATIVE THERAPIES

  11. Slide 11: Creating a global buyers' club that includes public and private payers

    CREATING A GLOBAL BUYERS’ CLUB THAT INCLUDES PUBLIC AND PRIVATE PAYERS ACROSS OECD COUNTRIES UNIVERSAL COVERAGE SYSTEMS. SINGLE PAYER SYSTEMS. REGIONAL PAYERS NATIONAL PAYERS EMPLOYER GROUPS: PHARMACY BENEFIT MANAGERS. HEALTH SYSTEMS & PROVIDERS PUBLIC PAYERS.

  12. Slide 12: Our model resonates broadly across different payers & health systems

    OUR MODEL RESONATES BROADLY ACROSS DIFFERENT PAYERS & HEALTH SYSTEMS eo \\ generate mat ceptance a medicines upon FDA approva REGIONAL PAYERS % \ : \ | Horizon — ‘ [| teathcare serves @ \\_ Mutsyear, stcteic partnership to make \ high-quality sines more accessible and Me eteduce Gra pera, by crestin

  13. Slide 13: Our model resonates broadly: EQRx and NHSE MOU

    OUR MODEL RESONATES BROADLY ACROSS DIFFERENT PAYERS & HEALTH SYSTEMS || EQRx and NHSE Sign Memorandum @ Bee EAE STEEN \\ of Understanding to Enter into \ England's First Population Health \\\. Partnership for Cancer Drugs

  14. Slide 14: Our model resonates broadly across different payers & health systems

    OUR MODEL RESONATES BROADLY ACROSS DIFFERENT PAYERS & HEALTH SYSTEMS Oxi 7OM+ REGIONAL PAYERS SINGLE PAYER SYSTEMS INTEGRATED DELIVERY NETWORKS LIVES COVERED

  15. Slide 15: New partnerships: Geisinger

    3 NEW PARTNERSHIPS / ee | Geisinger Geisinger and EQRx sign MOU providing \ roadmap for patient access to EQRx’s pipeline of e@ \\ innovative medicines upon FDA approval INTEGRATED DELIVERY \\ Network \\ Expansion of an existing long-term, strategic partnership between the two organizations

  16. Slide 16: New partnerships: Blue Shield of California

    3 NEW PARTNERSHIPS ] iN california REGIONAL PAYER e \| Blue Shield of California and EQRx are \\ collaborating to further their common goals \ to help ensure every person has safe, \ equitable access to sustainably affordable prescription drugs and lower overall healthcare costs

  17. Slide 17: New partnerships: CVS Health

    3 NEW PARTNERSHIPS e ¥CvSHealth. | CVS Health and EQRx sign MOU to explore | opportunities to enter into a long term, strategic ANIA, partnership spanning the CVS enterprise to improve access to innovative, lower-cost medicines to CVS Health clients, patients and members BENEFIT MANAGER | oO & NATIO

  18. Slide 18: New partnerships

    3 NEW PARTNERSHIPS @ @ ae @ ADDITIONAL LIVES @ — y, @ LIVES COVERED

  19. Slide 19: Payer pull through anticipated to increase adoption

    PAYER PULL THROUGH ANTICIPATED TO INCREASE ADOPTION WITHIN THE COVERED LIVES OF OUR GLOBAL BUYERS’ CLUB ‘TRADITIONAL THERAPEUTIC ACCESS i L COVERED LIVES h STRENGTH OF PULL MODEL Aligned incentives maximize adoption 44444) TT erry

  20. Slide 20: Current partners cover 180M lives

    CURRENT PARTNERS COVER 180M: LIVES PLUS DISTRIBUTION PARTNERSHIP Abdul Latif Jameel @ HEALTH

  21. Slide 21: Targeting the highest cost burden to patients and payers

    TARGETING THE HIGHEST COST BURDEN TO PATIENTS AND PAYERS Ya FLAMMATORY $500B GLOBAL SPEND ADDRESSED

  22. Slide 22: Scaling rapidly with 10+ programs today

    SCALING RAPIDLY - WITH 10+ PROGRAMS TODAY ADDRESSING ~$100B+ OF GLOBAL DRUG SPEND $1 triton ea ONCOLOGY & IMMUNE-INFLAMMATORY DISEASES PRE-REGISTRATIONAL CLINICAL, 5+ PRE-CLINICAL / DISCOVERY

  23. Slide 23: Portfolio of high-quality medicines: Aumolertinib

    PORTFOLIO OF HIGH-QUALITY MEDICINES GENERATING DATA PEOPLE WANT TO SEE AUMOLERTINIB | EGFR INHIBITOR + Significantly prolongs PFS (HR=0.46) with fewer side effects vs. gefitinib in Phase 3 first-line EGFR-mutated NSCLC (p-value < 6.0001) + 700+ patients treated in clinical trials + Drug approved in

  24. Slide 24: Portfolio of high-quality medicines: Sugemalimab

    PORTFOLIO OF HIGH-QUALITY MEDICINES GENERATING DATA PEOPLE WANT TO SEE SUGEMALIMAB | PD-L1 + Significantly prolongs PFS in Stage Ill and Stage IV NSCLC (HR=0.64 and 0.48, respectively), across pathologic sub-types (p- values 0.0026 and <0.0001, respectively) + 1,600* patients treated in clinical tri

  25. Slide 25: Targeting 20+ programs in 2022

    TARGETING 20+ PROGRAMS IN 2022 oncoLoey, IMMUNE-INFLAMMA DISEASES & OTHERS +$100B on... ADDRESSED

  26. Slide 26: Building our catalog through in-licensing

    BUILDING OUR CATALOG THROUGH IN-LICENSING Including our first 5 clinical & several preclinical programs PHARMA BIOTECH

  27. Slide 27: Building our catalog through drug engineering collaborations

    BUILDING OUR CATALOG THROUGH DRUG ENGINEERING COLLABORATIONS Including & partners today @Exscientia @ evotec <Jrevay (AStetera QB ADSci ENGINEERING. IN-LICENSING

  28. Slide 28: What enables this platform?

    WRAT ENABLES [HIS PLATFORM’

  29. Slide 29: Designing a highly efficient model

    DESIGNING A HIGHLY EFFICIENT MODEL HIGHER EXPECTED SUCCESS RATE 50-70% anticipated by argeting knowin Bolo teostiea wy, EFFICIENT DRUG DEVELOPMENT Evidence generation to adoption Madernized trial operations 3 STREAMLINED COMMERCIAL MODEL Payer partnerships generate the pull Data science native

  30. Slide 30: Offering radically lower prices

    OFFERI RADICALLY LOWER PRICES Sustainable pricing for yayers & health systems

  31. Slide 31: The EQRx platform today

    THE EQRx PLATFORM TODAY + RAISED >$2B $100B+ + RED 250 180M+ GLOBAL SPEND ADDRESSED LIVES COVERED

  32. Slide 32: Expected catalysts in the year ahead

    EXPECTED CATALYSTS IN THE YEAR AHEAD Announce additional first-of-kind partnerships with payers and providers CATALOG OF MEDICINES ( <or. \\_ GLOBAL BUYERS’ CLUB BUYERS’ CLUB First regulatory filings in H2 2022 Expand to 20+ programs and $200B+ global drug Expand to 350M+ spend partnership lives KEY

  33. Slide 33: Growth horizons

    GROWTH HORIZONS PEND ADDRESSED TODAY 2023-2027 2028 & BEYOND Building scale in our Pau reling medias PLATFORM AT SCALE pipeline and payer JUIN SAS HEMOUSS Unprecedented access to partnerships Sealgieipatne payer nimmeusitic uncetetass tarell

  34. Slide 34: Growth horizons

    GROWTH HORIZONS SPEND ADDRESSED TODAY 2023-2027 2028 & BEYOND Building scale in our Launching medicines: PLATFORM AT SCALE pipeline and payer elivering revenues Unprecedented access to recaps Sealing pipetine & payer nimmeusitic uncetetass tarell

  35. Slide 35: Growth horizons

    GROWTH HORIZONS SPEND ADDRESSED TODAY 2023-2027 2028 & BEYOND Building scale in our Peliehinglneci cies, PLATFORM AT SCALE pipeline and payer Saale Kea Unprecedented access to recaps Sealgieipatne payer innovative medicines for all

  36. Slide 36: New Pharma

    NEV PHARMA

EQRx — Investor Presentation (January 2022) on 6ix